{
    "ticker": "COEP",
    "name": "Coeptis Therapeutics, Inc.",
    "description": "Coeptis Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapeutic solutions for cancer treatment. Founded in 2016, the company is dedicated to advancing cell therapy and immunotherapy approaches to combat various forms of cancer. Coeptis is particularly known for its proprietary technology platforms that enhance the efficacy of therapeutic agents, including its focus on T-cell therapies. The company's lead product candidate, which is in clinical development, aims to harness the power of the immune system to target and destroy cancer cells more effectively while minimizing harm to healthy tissues. Coeptis is committed to improving patient outcomes by pursuing novel treatment strategies that can provide hope to patients facing challenging cancers. With a team of experienced scientists and industry veterans, Coeptis is well-positioned to make significant contributions to the field of oncology, striving to transform the standard of care for cancer patients. The company is actively collaborating with leading research institutions and clinical partners to expedite the development of its therapies, ensuring a strong pipeline of innovative treatment options.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Pittsburgh, Pennsylvania, USA",
    "founded": "2016",
    "website": "https://www.coeptistx.com",
    "ceo": "Jeffrey M. McNally",
    "social_media": {
        "twitter": "https://twitter.com/CoeptisTx",
        "linkedin": "https://www.linkedin.com/company/coeptis-therapeutics/"
    },
    "investor_relations": "https://www.coeptistx.com/investor-relations",
    "key_executives": [
        {
            "name": "Jeffrey M. McNally",
            "position": "CEO"
        },
        {
            "name": "Eric J. Dube",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "T-cell therapies",
                "Immunotherapy agents"
            ]
        }
    ],
    "seo": {
        "meta_title": "Coeptis Therapeutics, Inc. | Innovative Cancer Treatments",
        "meta_description": "Coeptis Therapeutics, Inc. is dedicated to developing cutting-edge therapies for cancer treatment. Explore our innovative approaches and commitment to patient care.",
        "keywords": [
            "Coeptis Therapeutics",
            "Biotechnology",
            "Cancer Treatment",
            "Immunotherapy",
            "Oncology",
            "T-cell Therapy"
        ]
    },
    "faq": [
        {
            "question": "What does Coeptis Therapeutics focus on?",
            "answer": "Coeptis Therapeutics focuses on developing innovative therapeutic solutions for cancer treatment, particularly through cell and immunotherapy."
        },
        {
            "question": "Who is the CEO of Coeptis Therapeutics?",
            "answer": "Jeffrey M. McNally is the CEO of Coeptis Therapeutics, Inc."
        },
        {
            "question": "Where is Coeptis Therapeutics headquartered?",
            "answer": "Coeptis Therapeutics is headquartered in Pittsburgh, Pennsylvania, USA."
        },
        {
            "question": "What are the main products of Coeptis Therapeutics?",
            "answer": "The main products include T-cell therapies and immunotherapy agents aimed at treating various cancers."
        },
        {
            "question": "When was Coeptis Therapeutics founded?",
            "answer": "Coeptis Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "CRSP",
        "SGMO",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "NVS",
        "BMY",
        "GILD"
    ]
}